




WHERE WE INVESTED, 2016-2017

Alberta 	British Columbia 	Manitoba 	New Brunswick 	Newfoundland/Labrador 	Nova Scotia 	Ontario 	Québec 	Saskatchewan 
---	---	---	--	--	--	--	---	---



RESEARCH FUNDING PROFILE

Order Based on Total Funding	Province	Principal Investigator, Institution, Awards	Title of Project	Funding Period	Amount
1		Dr. Elizabeth Tullis St. Michael's Hospital, Toronto <i>Matched Funding program</i>	Cystic Fibrosis Canada Chair in Adult Cystic Fibrosis Research at St. Michael's Hospital, Toronto	2014-2018	\$500,001
2		Dr. Daniela Rotin The Hospital for Sick Children, Toronto	Kinase inhibitors as correctors of F508del-CFTR	2015 - 2018	\$372,015
3		Dr. Julie Forman-Kay The Hospital for Sick Children, Toronto	Studying the regulatory (R) region of the CFTR protein and its role in controlling ion balance in the cell.	2016 - 2019	\$373,782
4		Dr. Neil Sweezey The Hospital for Sick Children, Toronto	Narrowing the gender gap: Modulating estrogen / IL-17 signaling to control Th17 cells and neutrophil extracellular traps in the cystic fibrosis lung	2015-2018	\$372,925
5		Dr. Lisa Strug, The Hospital for Sick Children, Toronto <i>2016 Senior Scientist Awardee</i>	Understanding the genetic epidemiology of cystic fibrosis	2016 - 2019	\$361,713
6		Dr. Shaf Keshavjee Toronto General Hospital, Toronto	Tissue remodelling and the immune response in obliterative bronchiolitis after lung transplantation	2015 - 2018	\$358,966
7		Dr. Valerie Waters The Hospital for Sick Children, Toronto	Conducting a randomized controlled trial of prednisone in cystic fibrosis (CF) pulmonary exacerbations (PIPE Study)	2016 - 2019	\$356,419
8		Dr. John Hanrahan McGill University, Montreal	Role of bicarbonate and mucus in airway innate immunity	2015 - 2018	\$350,068
9		Dr. Jim Hu University of Toronto, Toronto	Permanent correction of CF lung disease via site-specific insertion of a human CFTR gene expression cassette into the genome of the airway epithelial progenitor cells	2015 - 2018	\$338,308
10		Dr. Thien-Fah Mah, University of Ottawa, Ottawa	Understanding biofilm-specific antibiotic resistance to develop more effective therapies against bacterial infections	2013 - 2017 (no cost ext.)	\$332,767
11		Dr. Charles Deber The Hospital for Sick Children, Toronto	Understanding the make-up of the CFTR protein for better drug design	2014-2017	\$324,549
12		Dr. Christine Bear The Hospital for Sick Children, Toronto	Individualizing cystic fibrosis therapy	2016 - 2019	\$320,951
13		Dr. Nades Palaniyar The Hospital for Sick Children, Toronto	Improving CF lung disease through pH-mediated correction of immune functions of neutrophils	2016 - 2019	\$318,764
14		Dr. Valerie Chappe Dalhousie University, Halifax	Evaluating the neuropeptide VIP as a therapy to correct F508del-CFTR	2014-2017	\$313,164

15		Dr. Chris Mody University of Calgary, Calgary	Understanding the role of natural killer cells in immune defense against <i>B. cepacia</i>	2013 - 2017 (no cost ext.)	\$312,858
16		Dr. Paul Linsdell Dalhousie University, Halifax	Understanding how a new class of potentiators works to increase the activity of the CFTR protein	2014-2017	\$304,392
17		Dr. Emile Levy Université de Montréal, Montréal	Unraveling the role of microRNAs in intestinal cystic fibrosis disorders	2015 - 2018	\$301,344
18		Dr. Gergely Lukacs McGill University, Montreal	Understanding the architecture of misfolded proteins to design structure-based therapies	2016 - 2019	\$293,646
19		Dr. Robert Young Simon Fraser University, Burnaby <i>2016 Robbie Awardee</i>	Defining the molecular interactions and mapping the binding sites of CFTR "corrector" and "potentiator" drugs	2016 - 2019	\$292,161
20		Dr. David Clarke University of Toronto	Repair of CFTR defects caused by cystic fibrosis processing mutations	2015-2018	\$289,610
21		Dr. Francois Malouin University of Sherbrooke	Development of a combination therapy for MRSA and <i>Pseudomonas aeruginosa</i> in cystic fibrosis	2015-2018	\$287,480
22		Dr. Brian Mark University of Manitoba, Winnipeg	Finding small molecules that manipulate the genetics of <i>P. aeruginosa</i> to make it sensitive to antibiotics	2014-2017	\$284,125
23		Dr. Robert Hancock The University of British Columbia, Vancouver	Understanding antibiotic-resistance and developing new therapies against <i>P. aeruginosa</i>	2016 - 2019	\$272,412
24		Dr. Philip Britz-McKibbin McMaster University, Hamilton	Metabolomics for improved screening of cystic fibrosis: better diagnostics without carrier identification	2015-2018	\$268,613
25		Dr. Michael Murphy The University of British Columbia, Vancouver	Developing novel, target-specific therapeutics for the treatment of <i>Burkholderia cepacia</i> complex infections	2016 - 2019	\$268,098
26		Dr. Eric Brown McMaster University, Hamilton	Evaluating the use of previously-approved non-antibiotic drugs in combination with existing antibiotics to target CF infections	2014-2017	\$264,546
27		Dr. Stuart Turvey The University of British Columbia, Vancouver	Discovery of new anti-inflammatory therapies for cystic fibrosis empowered by enhanced understanding of the mechanisms of lung-damaging inflammation	2015 - 2018	\$264,150
28		Dr. Michael Surette McMaster University, Hamilton	Understanding the dynamic interactions of bacteria in the CF lung and their role in disease progression	2014-2017	\$263,592
29		Dr. Simon Rousseau McGill University, Montreal	Unravelling the complexity of IL-6 signaling in CF lung disease	2016 - 2019	\$260,118
30		Dr. Felix Ratjen The Hospital for Sick Children, Toronto	Evaluating LCI to monitor treatment response for pulmonary exacerbations	2016 - 2019	\$257,264
31		Dr. Bradley Quon St. Paul's Hospital, Vancouver <i>Matched Funding program</i>	Cystic Fibrosis Canada/UBC Clinician Scientist at St. Paul's Hospital	2014-2017	\$250,000
32		Dr. Keith Poole Queen's University, Kingston	Understanding antibiotic resistance in	2014-2017	\$249,517

			<i>Pseudomonas aeruginosa</i>		
33		Dr. Yves Berthiaume Université de Montréal, Montréal	Determining the link between the inflammatory molecule YKL-40 and the clinical evolution of CF and CFRD	2014-2017	\$243,957
34		Dr. David Speert The University of British Columbia, Vancouver	Investigating why some strains of <i>B. cepacia</i> complex cause severe lung infections in people with cystic fibrosis	2014-2017	\$240,945
35		Dr. Donald Sheppard McGill University, Montreal	Development of therapeutic agents for <i>Pseudomonas</i> and <i>Aspergillus</i> lung disease in cystic fibrosis	2015 - 2018	\$231,450

36		Dr. Genevieve Mailhot CHU Sainte-Justine Research Center, Montreal <i>Early Career Investigator Award</i>	Toward a better understanding of cystic fibrosis bone disease: Role of CFTR	2015-2017	\$222,563
37		Dr. Juan Ianowski University of Saskatchewan, Saskatoon	Testing whether mucus secretion is a normal airway response to bacteria in the CF pig	2014-2017	\$222,327
38		Dr. Shawn Lewenza University of Calgary, Calgary	Understanding the role of DNA in <i>P. aeruginosa</i> biofilms and how DNA promotes evasion of the immune response	2013 – 2016 (no cost ext.)	\$218,431
39		Dr. Ryszard Grygorczyk University of Montreal	Understanding the regulation of mucin release and rheology in cystic fibrosis	2016 – 2019	\$213,231
40		Dr. Rémi Rabasa-Lhoret IRCM, Montreal	Studying the effect of soluble fiber to reduce post-prandial glycemic excursion in adults with CF	2016-2019	\$197,666
41		Dr. Zhenyu Cheng Dalhousie University, Halifax <i>Marsha Morton Early Career Investigator Award</i>	Characterizing the antibiotic persistence mechanisms of <i>Pseudomonas aeruginosa</i>	2016 – 2018	\$196,680
42		Dr. Bryan Coburn University Health Network, Toronto <i>Early Career Investigator Award</i>	Personalized microbiology in cystic fibrosis pulmonary exacerbations: Assessing the pulmonary microbiota as a predictor of treatment response	2016 – 2018	\$166,977
43		Dr. Sarah Wootton University of Guelph, Guelph	Nuclease-based gene therapy for permanent correction of CF lung disease	2015 - 2017	\$155,703
44		Dr. Cory Yamashita Western University, London	Host-defense peptide fortified surfactant for the treatment of cystic fibrosis associated lung infections	2015-2017	\$147,862
45		Dr. Bradley Quon Centre for Heart Lung Innovation, Vancouver	External replication of a plasma protein bio-signature to predict cystic fibrosis pulmonary exacerbations	2015-2017	\$138,962
46		Dr. Michael Parkins University of Calgary	A neglected pathogen: Understanding the role of <i>Enterobacteriaceae</i> in cystic fibrosis lung disease	2016-2018	\$137,506
47		Ms. Nancy Alarie and Dr. Larry Lands Research Institute of the McGill University Health Centre, Montreal	Effects of a partially supervised conditioning program in CF: an international multi-centre, randomized controlled trial (ACTIVATE-CF)	2014-2016 (no cost ext.)	\$136,230
48		Dr. Remi Rabasa-Lhoret IRCM, Montreal	Relevance of 1h plasma glucose and insulin to identify adult CF patients at risk for diabetes as well as rapid pulmonary and nutritional decline	2014-2017	\$114,819
49		Dr. John Hanrahan & Dr. Janet Rossant McGill University, Montreal, & SickKids, Toronto <i>CIHR partnership</i>	Induced pluripotent stem cells for identification of novel drug combinations targeting cystic fibrosis lung and liver disease	2016-2018	\$105,000
50		Dr. Lori West University of Alberta, Edmonton <i>CIHR partnership</i>	The Canadian National Transplant Research Program: Increasing Donation and Improving Transplantation Outcomes	2013-2017	\$100,000

51		<p>Dr. Laurent Brochard St. Michael's Hospital, Toronto</p>	<p>Randomized cross-over physiologic study of High Flow nasal oxygEN cannula versus non-invasive ventilation in cystic fibrosis. The HIFEN study</p>	2015-2017	\$97,925
52		<p>Dr. Dao Nguyen McGill University, Montreal <i>Scholarship Award</i></p>	<p>Airway epithelial cell inflammatory response to <i>P. aeruginosa</i> clinical isolates and biofilms</p>	2013 - 2016	\$15,000